Bryan Garnier & Co advises GeNeuro on its Euronext IPO, raising €33 million, acting as Global Coordinator & Joint Bookrunner

GeNeuro tombstone
Share the transaction

Context

Founded in 2006, GeNeurois a spin-off from the InstitutMérieux group.Itis buildinga technological platform for developing new treatments targeting potential causes of neurological disorders and autoimmune diseases such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy and type1 diabetes.

GeNeuro’s first product, GNbAC1, is a monoclonal antibody that neutralizes a protein expressed by human endogenous retroviruses, which are part of the human genome that is normally silent. GeNeuro believes that this drug candidate could become the first treatment addressing a suspected causal factor of multiple sclerosis and therefore could radically change the way 2.5 million patients suffering from MS are treated.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Archamps, Haute-Savoie and Lyon, France. It has 20 employees and rights to 16 patent families protecting its technology.

Transaction highlights

  • Bryan, Garnier & Co acted as Global Coordinator & Joint Bookrunner for GeNeuro’s EUR 33m IPO.
  • The first Swiss IPO on Euronext Paris, with a public offer in France and an international placement in the rest of the world, including the United States.
  • Market capitalization at IPO: c.EUR 190m.
  • Solid book relying on long-only healthcare specialist and generalist investors.
  • Servier&InstitutMérieux’s participations demonstrate strong confidence in the company’s products, pipeline and capacity to execute.
  • IPO proceeds will be used to conduct preclinical and Phase II clinical studies, and strengthen the Company’s structure to prepare for planning and conducting a Phase III trial in the United States.
  • This marks another cross-border transaction for Bryan Garnier& Co’s healthcare team.

Team members

  • Olivier Garnier
  • Hervé Ronin
  • Romain Ellul

Privacy Preference Center